Changes in chemiluminescence of whole blood of COPD patients treated with Hypoxen® and effects of C60 fullerenes on blood chemiluminescence
Kirill N. Novikov, Nadezhda G. Berdnikova, Alexey K. Novikov, Oksana Y. Lyusina, Olga G. Muhitova, Olga I. Yablonskaya, Ha Do Minh, Vladimir L. Voeikov
Med Sci Monit 2012; 18(2): BR76-83
Available online: 2012-02-01
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory disease associated with reactive oxygen species (ROS) production. The aim of this study was to evaluate the effect of Hypoxen® treatment and the effect of HyFnC60 on ROS production in patients’ blood.
Material/Methods: ROS production in blood was estimated using chemiluminescence (CL) measurement with CL-amplifiers: luminol (LM), LM + zymosan (ZM) or lucigenin (LC) in the presence or absence of hydrated fullerenes (HyFnC60) added to blood in low concentrations.
Results: In all the patients with COPD in remission phase with Hypoxen® prescription, the LM-dependent CL (LM-CL) with ZM and LC-enhanced CL (LC-CL) decreased after the treatment. Parameters of CL and effects of HyFnC60 upon them depended on blood state. Addition of HyFnC60 to blood decreased data scattering and helped to improve discrimination between different groups of patients. Using the discriminator analysis, we found the most important time-points in the kinetic curves of CL for classification of patients into groups (eg, COPD patients before and after treatment with Hypoxen®; patients’ blood with different sensitivity to HyFnC60 concentration).
Conclusions: Monitoring of CL of non-diluted whole blood in COPD patients can be used for the estimation of the Hypoxen® efficiency in complex therapy. Addition of HyFnC60 to blood increases sensitivity of the method.
Keywords: Pulmonary Disease, Chronic Obstructive - drug therapy, Prospective Studies, Phenyl Ethers - therapeutic use, Luminescence, Fullerenes - therapeutic use, Reactive Oxygen Species - blood